open access

Vol 78, No 5 (2010)
GUIDELINES
Published online: 2010-08-10
Submitted: 2013-02-22
Get Citation

Zalecenia Polskiego Towarzystwa Chorób Płuc rozpoznawania i leczenia przewlekłej obturacyjnej choroby płuc (POChP)

Władysław Pierzchała, Adam Barczyk, Dorota Górecka, Paweł Śliwiński, Jan Zieliński
Pneumonol Alergol Pol 2010;78(5):318-347.

open access

Vol 78, No 5 (2010)
GUIDELINES
Published online: 2010-08-10
Submitted: 2013-02-22

Abstract

Not available

Abstract

Not available
Get Citation
About this article
Title

Zalecenia Polskiego Towarzystwa Chorób Płuc rozpoznawania i leczenia przewlekłej obturacyjnej choroby płuc (POChP)

Journal

Advances in Respiratory Medicine

Issue

Vol 78, No 5 (2010)

Pages

318-347

Published online

2010-08-10

Bibliographic record

Pneumonol Alergol Pol 2010;78(5):318-347.

Authors

Władysław Pierzchała
Adam Barczyk
Dorota Górecka
Paweł Śliwiński
Jan Zieliński

References (170)
  1. Celli BR, MacNee W. ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004; 23(6): 932–946.
  2. Rabe KF, Hurd S, Anzueto A, et al. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2007; 176(6): 532–555.
  3. Halbert RJ, Natoli JL, Gano A, et al. Global burden of COPD: systematic review and meta-analysis. Eur Respir J. 2006; 28(3): 523–532.
  4. Jemal A, Ward E, Hao Y, et al. Trends in the leading causes of death in the United States, 1970-2002. JAMA. 2005; 294(10): 1255–1259.
  5. Murray C, Lopez A. Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study. The Lancet. 1997; 349(9064): 1498–1504.
  6. Niepsuj G, Kozielski J, Niepsuj K, et al. Przewlekła obturacyjna choroba płuc wśród mieszkańców Zabrza. Wiad Lek. 2002; 55(supl. 1): 354–359.
  7. Nizankowska-Mogilnicka E, Mejza F, Buist AS, et al. Prevalence of COPD and tobacco smoking in Malopolska region--results from the BOLD study in Poland. Pol Arch Med Wewn. 2007; 117(9): 402–410.
  8. Pływaczewski R, Maciejewski J, Bednarek M, et al. Prevalence, severity and underdiagnosis of COPD in the primary care setting. Thorax. 2008; 63(5): 402–407.
  9. Rocznik statystyczny Rzeczpospolitej Polskiej. Główny Urząd Statystyczny 2008.
  10. Korzeniewska-Koseła M. Gruźlica i choroby układu oddechowego w Polsce. Instytut Gruźlicy i Chorób Płuc, Warszawa 2008.
  11. Young RP, Hopkins R, Eaton TE. Forced expiratory volume in one second: not just a lung function test but a marker of premature death from all causes. Eur Respir J. 2007; 30(4): 616–622.
  12. Blanc PD, Menezes AMB, Plana E, et al. Occupational exposures and COPD: an ecological analysis of international data. Eur Respir J. 2009; 33(2): 298–304.
  13. Hnizdo E, Sullivan PA, Bang KiM, et al. Association between chronic obstructive pulmonary disease and employment by industry and occupation in the US population: a study of data from the Third National Health and Nutrition Examination Survey. Am J Epidemiol. 2002; 156(8): 738–746.
  14. Schindler C, Keidel D, Gerbase MW, et al. SAPALDIA Team. Improvements in PM10 exposure and reduced rates of respiratory symptoms in a cohort of Swiss adults (SAPALDIA). Am J Respir Crit Care Med. 2009; 179(7): 579–587.
  15. Barker DJ, Godfrey KM, Fall C, et al. Relation of birth weight and childhood respiratory infection to adult lung function and death from chronic obstructive airways disease. BMJ. 1991; 303(6804): 671–675.
  16. Stoller J, Aboussouan L. α1-antitrypsin deficiency. The Lancet. 2005; 365(9478): 2225–2236.
  17. Barnes PJ, Shapiro SD, Pauwels RA. Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur Respir J. 2003; 22(4): 672–688.
  18. MacNee W. Oxidative stress and lung inflammation in airways disease. Eur J Pharmacol. 2001; 429(1-3): 195–207.
  19. Barnes P. Alveolar Macrophages as Orchestrators of COPD. COPD: Journal of Chronic Obstructive Pulmonary Disease. 2004; 1(1): 59–70.
  20. O'Shaughnessy TC, Ansari TW, Barnes NC, et al. Inflammation in bronchial biopsies of subjects with chronic bronchitis: inverse relationship of CD8+ T lymphocytes with FEV1. Am J Respir Crit Care Med. 1997; 155(3): 852–857.
  21. Thompson AB, Daughton D, Robbins RA, et al. Intraluminal airway inflammation in chronic bronchitis. Characterization and correlation with clinical parameters. Am Rev Respir Dis. 1989; 140(6): 1527–1537.
  22. Hogg JC, Chu F, Utokaparch S, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med. 2004; 350(26): 2645–2653.
  23. Hardie JA, Buist AS, Vollmer WM, et al. Risk of over-diagnosis of COPD in asymptomatic elderly never-smokers. Eur Respir J. 2002; 20(5): 1117–1122.
  24. Vollmer WM, Gíslason T, Burney P, et al. Comparison of spirometry criteria for the diagnosis of COPD: results from the BOLD study. Eur Respir J. 2009; 34(3): 588–597.
  25. Quanjer PH, Tammeling GJ, Cotes JE, et al. Lung volumes and forced ventilatory flows. Eur Respir J. 1993; 6 Suppl 16: 5–40.
  26. Falaschetti E, Laiho J, Primatesta P, et al. Prediction equations for normal and low lung function from the Health Survey for England. Eur Respir J. 2004; 23(3): 456–463.
  27. Penña V, Miravitlles M, Gabriel R, et al. Geographic Variations in Prevalence and Underdiagnosis of COPD. Chest. 2000; 118(4): 981–989.
  28. Fukuchi Y, Nishimura M, Ichinose M, et al. COPD in Japan: the Nippon COPD Epidemiology study. Respirology. 2004; 9(4): 458–465.
  29. Vestbo J, Prescott E, Lange P. Association of chronic mucus hypersecretion with FEV1 decline and chronic obstructive pulmonary disease morbidity. Copenhagen City Heart Study Group. Am J Respir Crit Care Med. 1996; 153(5): 1530–1535.
  30. Fletcher C, Peto R. The natural history of chronic airflow obstruction. Br Med J. 1977; 1(6077): 1645–1648.
  31. Burrows B, Kettel LJ, Niden AH, et al. Patterns of cardiovascular dysfunction in chronic obstructive lung disease. N Engl J Med. 1972; 286(17): 912–918.
  32. Celli BR, Cote CG, Marin JM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med. 2004; 350(10): 1005–1012.
  33. Rennard SI, Vestbo J. Natural histories of chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2008; 5(9): 878–883.
  34. Anthonisen NR, Connett JE, Murray RP. Smoking and lung function of Lung Health Study participants after 11 years. Am J Respir Crit Care Med. 2002; 166(5): 675–679.
  35. Zieliński J., Bednarek M., Górecka D. w imieniu grupy „Poznaj wiek swoich płuc”. Narodowy Program Wczesnego Rozpoznawania i Profilaktyki POChP w latach 2000–2002.
  36. Buffels J, Degryse J, Heyrman J, et al. DIDASCO Study. Office spirometry significantly improves early detection of COPD in general practice: the DIDASCO Study. Chest. 2004; 125(4): 1394–1399.
  37. Kohansal R, Martinez-Camblor P, Agustí A, et al. The natural history of chronic airflow obstruction revisited: an analysis of the Framingham offspring cohort. Am J Respir Crit Care Med. 2009; 180(1): 3–10.
  38. Lin K, Watkins B, Johnson T, et al. U.S. Preventive Services Task Force. Screening for chronic obstructive pulmonary disease using spirometry: summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2008; 148(7): 535–543.
  39. Anthonisen NR, Skeans MA, Wise RA, et al. Lung Health Study Research Group. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med. 2005; 142(4): 233–239.
  40. Kohansal R, Soriano JB, Agusti A. Investigating the natural history of lung function: facts, pitfalls, and opportunities. Chest. 2009; 135(5): 1330–1341.
  41. West R, McNeill A, Raw M. Smoking cessation guidelines for health professionals: an update. Health Education Authority. Thorax. 2000; 55(12): 987–999.
  42. Górecka D, Bednarek M, Nowiński A, et al. Diagnosis of airflow limitation combined with smoking cessation advice increases stop-smoking rate. Chest. 2003; 123(6): 1916–1923.
  43. Bednarek M, Gorecka D, Wielgomas J, et al. Smokers with airway obstruction are more likely to quit smoking. Thorax. 2006; 61(10): 869–873.
  44. Silagy C, Lancaster T, Stead L, et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2004(3): CD000146.
  45. Jorenby DE, Leischow SJ, Nides MA, et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med. 1999; 340(9): 685–691.
  46. Tashkin D, Kanner R, Bailey W, et al. Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomised trial. Lancet. 2001; 357(9268): 1571–1575.
  47. Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev. 2008(3): CD006103.
  48. 2008 PHS Guideline Update Panel, Liaisons, and Staff. Treating tobacco use and dependence: 2008 update U.S. Public Health Service Clinical Practice Guideline executive summary. Respir Care. 2008; 53(9): 1217–1222.
  49. Torres-Duque C, Maldonado D, Pérez-Padilla R, et al. Forum of International Respiratory Studies (FIRS) Task Force on Health Effects of Biomass Exposure. Biomass fuels and respiratory diseases: a review of the evidence. Proc Am Thorac Soc. 2008; 5(5): 577–590.
  50. Poole PJ, Chacko E, Wood-Baker RW, et al. Influenza vaccine for patients with chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2000(4): CD002733.
  51. Schembri S, Morant S, Winter JH, et al. Influenza but not pneumococcal vaccination protects against all-cause mortality in patients with COPD. Thorax. 2009; 64(7): 567–572.
  52. Schenkein JG, Nahm MH, Dransfield MT. Pneumococcal vaccination for patients with COPD: current practice and future directions. Chest. 2008; 133(3): 767–774.
  53. Dransfield MT, Nahm MH, Han MK, et al. COPD Clinical Research Network. Superior immune response to protein-conjugate versus free pneumococcal polysaccharide vaccine in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2009; 180(6): 499–505.
  54. Furumoto A, Ohkusa Y, Chen M, et al. Additive effect of pneumococcal vaccine and influenza vaccine on acute exacerbation in patients with chronic lung disease. Vaccine. 2008; 26(33): 4284–4289.
  55. Zalecenia skiego Towarzystwa Ftizjopneumonologicznego rozpoznawania i leczenia przewlekłej obturacyjnej choroby płuc (POChP). Pneumonol Alergol Pol. 2004; 72(supl. 1).
  56. Rodrigo GJ, Nannini LJ, Rodríguez-Roisin R. Safety of long-acting beta-agonists in stable COPD: a systematic review. Chest. 2008; 133(5): 1079–1087.
  57. Celli B, Decramer M, Kesten S, et al. UPLIFT Study Investigators, UPLIFT Study Investigators. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008; 359(15): 1543–1554.
  58. Decramer M, Celli B, Kesten S, et al. UPLIFT investigators. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet. 2009; 374(9696): 1171–1178.
  59. Wedzicha JA, Calverley PMA, Seemungal TA, et al. INSPIRE Investigators. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med. 2008; 177(1): 19–26.
  60. Johansson G, Lindberg A, Romberg K, et al. Bronchodilator efficacy of tiotropium in patients with mild to moderate COPD. Prim Care Respir J. 2008; 17(3): 169–175.
  61. Barr RG, Rowe BH, Camargo CA. Methylxanthines for exacerbations of chronic obstructive pulmonary disease: meta-analysis of randomised trials. BMJ. 2003; 327(7416): 643–649.
  62. Di Marco F, Verga M, Santus P, et al. Effect of formoterol, tiotropium, and their combination in patients with acute exacerbation of chronic obstructive pulmonary disease: a pilot study. Respir Med. 2006; 100(11): 1925–1932.
  63. Walters JAe, Gibson PG, Wood-Baker R, et al. Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2009(1): CD001288.
  64. Burge PS, Calverley PMA, Jones PW, et al. Prednisolone response in patients with chronic obstructive pulmonary disease: results from the ISOLDE study. Thorax. 2003; 58(8): 654–658.
  65. Alsaeedi A, Sin DD, McAlister FA. The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review of randomized placebo-controlled trials. Am J Med. 2002; 113(1): 59–65.
  66. Calverley P, Pauwels R, Vestbo J, et al. TRial of Inhaled STeroids ANd long-acting beta2 agonists study group. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 2003; 361(9356): 449–456.
  67. Szafranski W, Cukier A, Ramirez A, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J. 2003; 21(1): 74–81.
  68. Calverley PMA, Anderson JA, Celli B, et al. TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007; 356(8): 775–789.
  69. Nannini L, Cates CJ, Lasserson TJ, et al. Combined corticosteroid and long acting beta-agonist in one inhaler for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2004(3): CD003794.
  70. Nannini LJ, Cates CJ, Lasserson TJ, et al. Combined corticosteroid and long-acting beta-agonist in one inhaler versus inhaled steroids for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2007(4): CD006826.
  71. Nannini LJ, Cates CJ, Lasserson TJ, et al. Combined corticosteroid and long-acting beta-agonist in one inhaler versus inhaled steroids for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2007(4): CD006826.
  72. Celli BR, Thomas NE, Anderson JA, et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med. 2008; 178(4): 332–338.
  73. Jenkins CR, Jones PW, Calverley PMA, et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study. Respir Res. 2009; 10: 59.
  74. Singh D, Brooks J, Hagan G, et al. Superiority of "triple" therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD. Thorax. 2008; 63(7): 592–598.
  75. Najafzadeh M, Marra CA, Sadatsafavi M, et al. Canadian Thoracic Society/Canadian Respiratory Clinical Research Consortium. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med. 2007; 146(8): 545–555.
  76. Calverley PMA, Sanchez-Toril F, McIvor A, et al. Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007; 176(2): 154–161.
  77. Rennard SI, Schachter N, Strek M, et al. Cilomilast for COPD: results of a 6-month, placebo-controlled study of a potent, selective inhibitor of phosphodiesterase 4. Chest. 2006; 129(1): 56–66.
  78. Calverley PMA, Rabe KF, Goehring UM, et al. M2-124 and M2-125 study groups. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet. 2009; 374(9691): 685–694.
  79. Fabbri LM, Calverley PMA, Izquierdo-Alonso JL, et al. M2-127 and M2-128 study groups. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet. 2009; 374(9691): 695–703.
  80. Poole P, Black PN, Cates CJ, et al. Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2000; 322(2): CD001287.
  81. Zieliński J, Tobiasz M, Hawryłkiewicz I, et al. Effects of long-term oxygen therapy on pulmonary hemodynamics in COPD patients: a 6-year prospective study. Chest. 1998; 113(1): 65–70.
  82. Continuous or Nocturnal Oxygen Therapy in Hypoxemic Chronic Obstructive Lung Disease. Annals of Internal Medicine. 1980; 93(3): 391–398.
  83. Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Report of the Medical Research Council Working Party. Lancet. 1981; 1(8222): 681–686.
  84. Plywaczewski R, Sliwinski P, Nowinski A, et al. Incidence of nocturnal desaturation while breathing oxygen in COPD patients undergoing long-term oxygen therapy. Chest. 2000; 117(3): 679–683.
  85. Skwarski K. Nocna hipoksemia i zaburzenia rytmu serca u chorych z przewlekłą obturacyjną chorobą płuc. Pol Arch Med Wewn. 1989; 81: 283–294.
  86. Sliwiński P, Lagosz M, Górecka D, et al. The adequacy of oxygenation in COPD patients undergoing long-term oxygen therapy assessed by pulse oximetry at home. Eur Respir J. 1994; 7(2): 274–278.
  87. Goldstein RS, Ramcharan V, Bowes G, et al. Effect of supplemental nocturnal oxygen on gas exchange in patients with severe obstructive lung disease. N Engl J Med. 1984; 310(7): 425–429.
  88. O'Donnell DE, Bain DJ, Webb KA. Factors contributing to relief of exertional breathlessness during hyperoxia in chronic airflow limitation. Am J Respir Crit Care Med. 1997; 155(2): 530–535.
  89. Somfay A, Porszasz J, Lee SM, et al. Dose-response effect of oxygen on hyperinflation and exercise endurance in nonhypoxaemic COPD patients. Eur Respir J. 2001; 18(1): 77–84.
  90. Gong H. Air Travel and Oxygen Therapy in Cardiopulmonary Patients. Chest. 1992; 101(4): 1104–1113.
  91. Gong H. Jr., Taskhin D.P., Lee E.Y., Simmons M.S. Hypoxia altitude simulation test. Evaluation of patients with chronic airway obstruction. Am Rev Respir Dis. 1984; 130: 980–986.
  92. Berg BW, Dillard TA, Rajagopal KR, et al. Oxygen supplementation during air travel in patients with chronic obstructive lung disease. Chest. 1992; 101(3): 638–641.
  93. Walker J, Kelly PT, Beckert L. Air line policy for passengers requiring supplemental in-fligh oxygen. Respirology. 2009; 14: 589–594.
  94. Mehran RJ, Deslauriers J. Indications for surgery and patient work-up for bullectomy. Chest Surg Clin N Am. 1995; 5(4): 717–734.
  95. Hughes JA, MacArthur AM, Hutchison DC, et al. Long term changes in lung function after surgical treatment of bullous emphysema in smokers and ex-smokers. Thorax. 1984; 39(2): 140–142.
  96. Laros CD, Gelissen HJ, Bergstein PG, et al. Bullectomy for giant bullae in emphysema. J Thorac Cardiovasc Surg. 1986; 91(1): 63–70.
  97. Flaherty KR, Kazerooni EA, Curtis JL, et al. Short-term and long-term outcomes after bilateral lung volume reduction surgery : prediction by quantitative CT. Chest. 2001; 119(5): 1337–1346.
  98. Gelb AF, McKenna RJ, Brenner M, et al. Lung function 5 yr after lung volume reduction surgery for emphysema. Am J Respir Crit Care Med. 2001; 163(7): 1562–1566.
  99. Naunheim KS, Wood DE, Mohsenifar Z, et al. National Emphysema Treatment Trial Research Group. Long-term follow-up of patients receiving lung-volume-reduction surgery versus medical therapy for severe emphysema by the National Emphysema Treatment Trial Research Group. Ann Thorac Surg. 2006; 82(2): 431–443.
  100. Hamacher J, Russi EW, Weder W. Lung volume reduction surgery: a survey on the European experience. Chest. 2000; 117(6): 1560–1567.
  101. Hosenpud JD, Bennett LE, Keck BM, et al. The Registry of the International Society for Heart and Lung Transplantation: fifteenth official report--1998. J Heart Lung Transplant. 1998; 17(7): 656–668.
  102. Maurer JR, Frost AE, Estenne M, et al. International guidelines for the selection of lung transplant candidates. The International Society for Heart and Lung, the American Thoracic Society, the American Society of Transplant Physicians, the European Respiratory Society. Transplantation. 1998; 66: 951–956.
  103. Gosselink R, Troosters T, Decramer M. Peripheral muscle weakness contributes to exercise limitation in COPD. Am J Respir Crit Care Med. 1996; 153(3): 976–980.
  104. Goldstein RS, Gort EH, Guyatt GH, et al. Randomised controlled trial of respiratory rehabilitation. Lancet. 1994; 344(8934): 1394–1397.
  105. Troosters T, Casaburi R, Gosselink R, et al. Pulmonary rehabilitation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2005; 172(1): 19–38.
  106. O'Donnell DE, McGuire M, Samis L, et al. The impact of exercise reconditioning on breathlessness in severe chronic airflow limitation. Am J Respir Crit Care Med. 1995; 152(6 Pt 1): 2005–2013.
  107. Casaburi R, Kukafka D, Cooper CB, et al. Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD. Chest. 2005; 127(3): 809–817.
  108. Behnke M, Taube C, Kirsten D, et al. Home-based exercise is capable of preserving hospital-based improvements in severe chronic obstructive pulmonary disease. Respir Med. 2000; 94(12): 1184–1191.
  109. Troosters T, Gosselink R, Decramer M. Short- and long-term effects of outpatient rehabilitation in patients with chronic obstructive pulmonary disease: a randomized trial. Am J Med. 2000; 109(3): 207–212.
  110. Finnerty JP, Keeping I, Bullough I, et al. The effectiveness of outpatient pulmonary rehabilitation in chronic lung disease: a randomized controlled trial. Chest. 2001; 119(6): 1705–1710.
  111. Green RH, Singh SJ, Williams J, et al. A randomised controlled trial of four weeks versus seven weeks of pulmonary rehabilitation in chronic obstructive pulmonary disease. Thorax. 2001; 56(2): 143–145.
  112. Gibson PG, Wlodarczyk JH, Wilson AJ, et al. Severe exacerbation of chronic obstructive airways disease: health resource use in general practice and hospital. J Qual Clin Pract. 1998; 18(2): 125–133.
  113. Mahler DA. Pulmonary rehabilitation. Chest. 1998; 113: 263S–268S.
  114. Bernard S, Whittom F, Leblanc P, et al. Aerobic and strength training in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1999; 159(3): 896–901.
  115. Smith K, Cook D, Guyatt GH, et al. Respiratory muscle training in chronic airflow limitation: a meta-analysis. Am Rev Respir Dis. 1992; 145(3): 533–539.
  116. Lötters F, van Tol B, Kwakkel G, et al. Effects of controlled inspiratory muscle training in patients with COPD: a meta-analysis. Eur Respir J. 2002; 20(3): 570–576.
  117. Brochard L, Mancebo J, Wysocki M, et al. Noninvasive ventilation for acute exacerbations of chronic obstructive pulmonary disease. N Engl J Med. 1995; 333(13): 817–822.
  118. Hillberg RE, Johnson DC. Noninvasive ventilation. N Engl J Med. 1997; 337(24): 1746–1752.
  119. Muir JF, Cuvelier A, Verin E, et al. Noninvasive mechanical ventilation and acute respiratory failure: indications and limitations. Monaldi Arch Chest Dis. 1997; 52(1): 56–59.
  120. Elliott MW. Noninvasive ventilation in chronic ventilatory failure due to chronic obstructive pulmonary disease. Eur Respir J. 2002; 20(3): 511–514.
  121. Clinical indications for noninvasive positive pressure ventilation in chronic respiratory failure due to restrictive lung disease, COPD, and nocturnal hypoventilation--a consensus conference report. Chest. 1999; 116(2): 521–534.
  122. Clini E, Sturani C, Rossi A, et al. Rehabilitation and Chronic Care Study Group, Italian Association of Hospital Pulmonologists (AIPO). The Italian multicentre study on noninvasive ventilation in chronic obstructive pulmonary disease patients. Eur Respir J. 2002; 20(3): 529–538.
  123. Pingleton SK. Invasive mechanical ventilation in exacerbations of chronic obstructive pulmonary disease. Monaldi Arch Chest Dis. 1998; 53(3): 337–342.
  124. Purro A, Appendini L, De Gaetano A, et al. Physiologic determinants of ventilator dependence in long-term mechanically ventilated patients. Am J Respir Crit Care Med. 2000; 161(4 Pt 1): 1115–1123.
  125. Nava S, Rubini F, Zanotti E, et al. Survival and prediction of successful ventilator weaning in COPD patients requiring mechanical ventilation for more than 21 days. Eur Respir J. 1994; 7(9): 1645–1652.
  126. Nevins ML, Epstein SK. Predictors of outcome for patients with COPD requiring invasive mechanical ventilation. Chest. 2001; 119(6): 1840–1849.
  127. Esteban A, Anzueto A, Alía I, et al. How is mechanical ventilation employed in the intensive care unit? An international utilization review. Am J Respir Crit Care Med. 2000; 161(5): 1450–1458.
  128. Caramori G, Adcock IM, Papi A. Clinical definition of COPD exacerbations and classification of their severity. South Med J. 2009; 102(3): 277–282.
  129. Pauwels R, Calverley P, Buist AS, et al. COPD exacerbations: the importance of a standard definition. Respir Med. 2004; 98(2): 99–107.
  130. Anthonisen NR, Manfreda J, Warren CP, et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med. 1987; 106(2): 196–204.
  131. Huchon G, Woodhead M, Gialdroni-Grassi G, et al. Guidelines for management of adult community-acquired lower respiratory tract infections. European Respiratory Journal. 1998; 11(4): 986–991.
  132. Cazzola M, MacNee W, Martinez FJ, et al. American Thoracic Society, European Respiratory Society Task Force on outcomes of COPD. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J. 2008; 31(2): 416–469.
  133. Wedzicha JA, Seemungal TAR. COPD exacerbations: defining their cause and prevention. Lancet. 2007; 370(9589): 786–796.
  134. Hurst JR, Donaldson GC, Wilkinson TMA, et al. Epidemiological relationships between the common cold and exacerbation frequency in COPD. Eur Respir J. 2005; 26(5): 846–852.
  135. Seemungal T, Harper-Owen R, Bhowmik A, et al. Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001; 164(9): 1618–1623.
  136. Yang CY, Chen CJ. Air pollution and hospital admissions for chronic obstructive pulmonary disease in a subtropical city: Taipei, Taiwan. J Toxicol Environ Health A. 2007; 70(14): 1214–1219.
  137. Linaker CH, Coggon D, Holgate ST, et al. Personal exposure to nitrogen dioxide and risk of airflow obstruction in asthmatic children with upper respiratory infection. Thorax. 2000; 55(11): 930–933.
  138. Holguin F, Folch E, Redd SC, et al. Comorbidity and mortality in COPD-related hospitalizations in the United States, 1979 to 2001. Chest. 2005; 128(4): 2005–2011.
  139. Tillie-Leblond I, Marquette CH, Perez T, et al. Pulmonary embolism in patients with unexplained exacerbation of chronic obstructive pulmonary disease: prevalence and risk factors. Ann Intern Med. 2006; 144(6): 390–396.
  140. Smeeth L, Cook C, Thomas S, et al. Risk of deep vein thrombosis and pulmonary embolism after acute infection in a community setting. Lancet. 2006; 367(9516): 1075–1079.
  141. Davies L, Angus RM, Calverley PM. Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial. Lancet. 1999; 354(9177): 456–460.
  142. Niewoehner DE, Erbland ML, Deupree RH, et al. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. N Engl J Med. 1999; 340(25): 1941–1947.
  143. Roede BM, Bresser P, Bindels PJE, et al. Antibiotic treatment is associated with reduced risk of a subsequent exacerbation in obstructive lung disease: an historical population based cohort study. Thorax. 2008; 63(11): 968–973.
  144. El Moussaoui R, Roede BM, Speelman P, et al. Short-course antibiotic treatment in acute exacerbations of chronic bronchitis and COPD: a meta-analysis of double-blind studies. Thorax. 2008; 63(5): 415–422.
  145. O’Donnell DE, Aaron S, et al. adian Thoracic Society recommendations for management of chronic obstructive pulmonary disease — 2007 update. Can Respir J. 2007; 14: 5B–32B.
  146. Burge PS, Calverley PM, Jones PW, et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ. 2000; 320(7245): 1297–1303.
  147. Wise R, Connett J, Weinmann G, et al. Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med. 2000; 343(26): 1902–1909.
  148. Niewoehner DE, Rice K, Cote C, et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial. Ann Intern Med. 2005; 143(5): 317–326.
  149. Casaburi R, Mahler DA, Jones PW, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J. 2002; 19(2): 217–224.
  150. Rennard SI, Anderson W, ZuWallack R, et al. Use of a long-acting inhaled beta2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001; 163(5): 1087–1092.
  151. Aaron SD, Vandemheen KL, Fergusson D, et al. Canadian Thoracic Society/Canadian Respiratory Clinical Research Consortium. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med. 2007; 146(8): 545–555.
  152. Gorse GJ, O'connor TZ, Young SL, et al. Impact of a winter respiratory virus season on patients with COPD and association with influenza vaccination. Chest. 2006; 130(4): 1109–1116.
  153. Alfageme I, Vazquez R, Reyes N, et al. Clinical efficacy of anti-pneumococcal vaccination in patients with COPD. Thorax. 2006; 61(3): 189–195.
  154. Solèr M, Mütterlein R, Cozma G, et al. Swiss-German OM-85 Study Group. Double-blind study of OM-85 in patients with chronic bronchitis or mild chronic obstructive pulmonary disease. Respiration. 2007; 74(1): 26–32.
  155. Sprenkle MD, Niewoehner DE, MacDonald R, et al. Clinical efficacy of OM-85 BV in COPD and chronic bronchitis: a systematic review. COPD. 2005; 2(1): 167–175.
  156. Kunik ME, Roundy K, Veazey C, et al. Surprisingly high prevalence of anxiety and depression in chronic breathing disorders. Chest. 2005; 127(4): 1205–1211.
  157. Bailey P. The Dyspnea-Anxiety-Dyspnea Cycle—COPD Patients’ Stories of Breathlessness: “It’s Scary /When you Can’t Breathe”. Qualitative Health Research. 2004; 14(6): 760–778.
  158. Gudmundsson G, Gislason T, Janson C, et al. Risk factors for rehospitalisation in COPD: role of health status, anxiety and depression. Eur Respir J. 2005; 26(3): 414–419.
  159. de Voogd JN, Wempe JB, Koëter GH, et al. Depressive symptoms as predictors of mortality in patients with COPD. Chest. 2009; 135(3): 619–625.
  160. Curtis JR, Engelberg R, Young JP, et al. Patient-physician communication about end-of-life care for patients with severe COPD. Eur Respir J. 2004; 24(2): 200–205.
  161. Jones I, Kirby A, Ormiston P, et al. The needs of patients dying of chronic obstructive pulmonary disease in the community. Fam Pract. 2004; 21(3): 310–313.
  162. O'Donnell DE, Banzett RB, Carrieri-Kohlman V, et al. Pathophysiology of dyspnea in chronic obstructive pulmonary disease: a roundtable. Proc Am Thorac Soc. 2007; 4(2): 145–168.
  163. Paz-Díaz H, Montes de Oca M, López JM, et al. Pulmonary rehabilitation improves depression, anxiety, dyspnea and health status in patients with COPD. Am J Phys Med Rehabil. 2007; 86(1): 30–36.
  164. Gore JM, Brophy CJ, Greenstone MA. How well do we care for patients with end stage chronic obstructive pulmonary disease (COPD)? A comparison of palliative care and quality of life in COPD and lung cancer. Thorax. 2000; 55(12): 1000–1006.
  165. Hung WW, Wisnivesky JP, Siu AL, et al. Cognitive decline among patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2009; 180(2): 134–137.
  166. Virchow JC, Crompton GK, Dal Negro R, et al. Importance of inhaler devices in the management of airway disease. Respir Med. 2008; 102(1): 10–19.
  167. Budweiser S, Hitzl AP, Jörres RA, et al. Health-related quality of life and long-term prognosis in chronic hypercapnic respiratory failure: a prospective survival analysis. Respir Res. 2007; 8: 1–9.
  168. Croft M. Palliative care in end-stage COPD. Br J Gen Pract. 2005; 55(512): 234–235.
  169. Murray SA, Kendall M, Boyd K, et al. Illness trajectories and palliative care. BMJ. 2005; 330(7498): 1007–1011.
  170. Buchanan R, Chakravorty B, Wang S, et al. Nursing Home Residents with Emphysema/COPD Compared to Other Residents. Journal of Social Work in Disability & Rehabilitation. 2004; 3(1): 53–78.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Czasopismo Pneumonologia i Alergologia Polska dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl